Odanacatib

From Self-sufficiency
Jump to: navigation, search
Odanacatib
File:Odanacatib.png
Systematic (IUPAC) name
N-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide
Clinical data
Routes of
administration		 oral
Identifiers
CAS Number 603139-19-1
ATC code none
PubChem CID 10152654
Synonyms (2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide
Chemical data
Formula C25H27F4N3O3S
Molar mass 525.56 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis[1]. It is an inhibitor of cathepsin K,[2] an enzyme involved in bone resorption.

It is being developed by Merck & Co. As of November 2009, Merck is conducting phase III clinical trials.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
Drugs for treatment of bone diseases (M05)
Bisphosphonates
Bone morphogenetic proteins
Other
Resorption inhibitor (Ipriflavone) · Aluminium chlorohydrate · Dual action bone agent (Strontium ranelate) ·
RANKL inhibitor (Denosumab) · Cathepsin K inhibitor (Odanacatib)


45px This drug article relating to the musculoskeletal system is a stub. You can help ssf by expanding it.
  1. ↑ Le Gall, C. L.; Bonnelye, E.; Clézardin, P. (2008). "Cathepsin K inhibitors as treatment of bone metastasis". Current Opinion in Supportive and Palliative Care. 2 (3): 218. doi:10.1097/SPC.0b013e32830baea9. PMID 18685424.  edit
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Odanacatib&oldid=21366"